Virtual Incentive Treatment for Alcohol

Description

The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth \>= 200 ng/mL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.

Conditions

Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth \>= 200 ng/mL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.

Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults With AUD

Virtual Incentive Treatment for Alcohol

Condition
Alcohol Use Disorder
Intervention / Treatment

-

Contacts and Locations

Spokane

Washington State University, Spokane, Washington, United States, 99201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Had 2 heavy drinking episodes (assigned male at birth \> 4 standard drinks (SDs), assigned female at birth \> 3 SDs) or ≥14 SDs in the prior 14 days verified by PEth 16:0/18:1 biomarker \> 20 ng/mL (indicates at least 2 heavy drinking episodes in past two weeks);
  • 2. Have a DSM-5 diagnosis of a current AUD as assessed by the Structured Clinical Interview for DSM-5;
  • 3. 18+ (individuals over 65 will be assessed for cognitive impairments)
  • 4. Are not receiving treatment for AUD
  • 5. Are able to complete virtual study visits via Zoom
  • 1. have a current diagnosis of severe substance use disorder (other than AUD, tobacco, and cannabis);
  • 2. PEth biomarker ≤ 20 ng/mL (indicates no heavy drinking in past month)
  • 3. inability to provide informed consent based on the UBACC or MacCAT-CR;
  • 4. alcohol withdrawal-related seizure or hospitalization in prior 12 months;
  • 5. psychiatrically or medically unsafe to participate, as assessed by the PI; and/or
  • 6. currently enrolled in alcohol treatment or another alcohol treatment study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington State University,

Michael McDonell, PhD, PRINCIPAL_INVESTIGATOR, Washington State University Elson S. Floyd College of Medicine

Nathalie Hill-Kapturczak, PhD, PRINCIPAL_INVESTIGATOR, University of Texas Health San Antonio

Sean Murphy, PhD, PRINCIPAL_INVESTIGATOR, Weill Cornell

Study Record Dates

2028-04-04